Bullish post on SLS arguing shorts are struggling to cover and that positive Phase 3 REGAL trial data could trigger a buyout, FDA approval, or short squeeze.
SLS — LONG The author argues shorts in SLS are having difficulty covering and that when Phase 3 data from the REGAL trial is read out it will be a major event. The author states the outcome will likely be either a buyout, which they put at a 25% chance that rises with data quality, or FDA approval. The author adds that short positioning could cause a squeeze, and cites the company's team and science as remarkable.
When phase 3 from the REGAL trial completes and the data is read it will be a bomb.
This Reddit post, published January 16, 2026, features u/zacheezy discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/zacheezy · Tickers: SLS